Smoking Cessation

Nicotine dependence is a medical condition

Smoking is not simply a lifestyle choice or habit. It is a form of nicotine dependence involving neurochemical adaptation within the brain. Repeated nicotine exposure alters nicotinic acetylcholine receptor activity and reinforces behavioural associations with daily routines.

When nicotine intake stops, withdrawal symptoms commonly develop. You may notice irritability, restlessness, reduced concentration, low mood, sleep disturbance and strong urges to smoke. These symptoms are temporary but can feel intense in the early stages.

Effective cessation strategies address both the biological dependence and the learned behavioural patterns linked to smoking.

Why combined approaches are commonly recommended

Clinical guidelines support the use of pharmacotherapy alongside behavioural support because this combination is associated with higher sustained abstinence rates compared with unassisted quitting.

Medication helps reduce withdrawal symptoms. Behavioural strategies assist with trigger identification, coping skills and relapse prevention. Addressing both elements increases the likelihood of maintaining cessation.

Pharmacotherapy options

Pharmacological treatment may be considered for adults with nicotine dependence following clinical assessment.

Nicotine Replacement Therapy

Nicotine Replacement Therapy (NRT) delivers nicotine without exposure to tobacco smoke toxins.

Forms include:

• Transdermal patches
• Gum
• Lozenges
• Inhalators
• Oral sprays

Long-acting patches provide steady nicotine levels, while short-acting products address breakthrough cravings. Combination use may be considered under clinical guidance.

Duration and dosing should be individualised in consultation with a GP or pharmacist.

Varenicline

Varenicline is a partial nicotinic receptor agonist. It reduces withdrawal symptoms and decreases the reinforcing effects of nicotine. It is available by prescription and requires medical assessment for suitability.

Possible adverse effects include nausea and sleep disturbance. Your GP will discuss risks, benefits and monitoring requirements.

Bupropion

Bupropion is a sustained-release medication that can reduce cravings and withdrawal symptoms. It may be considered in selected individuals.

Because it lowers seizure threshold in susceptible patients, careful medical assessment is required before initiation.

Other medicines

Additional medications such as nortriptyline or clonidine may be considered in specific clinical circumstances where first-line options are unsuitable.

Cytisine is used in some countries; regulatory status and availability vary.

Behavioural and support strategies

Pharmacotherapy addresses physiological withdrawal. Behavioural interventions address psychological reinforcement and relapse risk.

Brief intervention in general practice

Your GP may use structured approaches such as:

• Ask about smoking status
• Advise cessation in a clear, non-judgemental manner
• Assist with a tailored plan

More comprehensive models include structured follow-up and behavioural planning.

Counselling and structured support

Behavioural support may involve:

• Individual counselling
• Cognitive behavioural therapy
• Motivational interviewing
• Relapse prevention planning

Telephone-based support such as Quitline (13 78 48 in Australia) provides confidential coaching and structured follow-up.

Digital tools, including evidence-based mobile applications, may support daily accountability and tracking.

Managing cravings in the short term

Cravings often peak and subside within several minutes.

Strategies may include:

• Delaying action
• Slow breathing
• Hydration
• Brief distraction
• Physical movement

Repeated practice strengthens coping capacity.

Complementary approaches

Acupuncture and hypnotherapy are sometimes explored. Current evidence does not consistently demonstrate long-term effectiveness comparable to established medical and behavioural treatments.

Exercise and mindfulness practices may support stress reduction and overall wellbeing but are best used as adjuncts rather than primary cessation strategies.

Emerging interventions such as Transcranial Magnetic Stimulation remain under investigation and are not standard first-line therapy.

Special considerations

Additional assessment and monitoring may be required if you:

• Are pregnant or breastfeeding
• Have significant mental health conditions
• Have cardiovascular disease
• Use multiple medications

Smoking cessation is associated with improved cardiovascular health and long-term reduction in preventable disease risk.

Planning a structured quit attempt

Preparation improves success.

• Choose a quit date
• Remove tobacco products from your environment
• Inform supportive contacts
• Arrange follow-up with your GP within the first one to two weeks

Relapse can occur and does not represent failure. It provides information for refining future attempts.

Clinical perspective

Smoking remains a leading contributor to preventable illness in Australia. Evidence-informed treatment significantly improves the likelihood of long-term cessation compared with unassisted attempts.

Discussing cessation early — even before you feel ready — allows planning in a supportive, structured manner.

This article provides general health information only and does not replace medical advice. Please speak with your GP for personalised care.